<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57000">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882933</url>
  </required_header>
  <id_info>
    <org_study_id>2012.761</org_study_id>
    <nct_id>NCT01882933</nct_id>
  </id_info>
  <brief_title>D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma</brief_title>
  <acronym>GASTRICHIP</acronym>
  <official_title>GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A National Randomized and Multicentric Phase III Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, opened, multicentric, randomised, phase III trial with two arms:

        -  Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin

        -  Arm B: curative gastrectomy with D1-D2 lymph node dissection

      Main objective: Compare overall 5-year survival rates in patients surgically treated for
      advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology),
      treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>From the date of surgery to the date of death or to the end of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>From the date of surgery to the date of recurrence or to the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>From the date of surgery to the date of recurrence or to the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional-free survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>From the date of surgery to the date of locoregional recurrence or to the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related morbidity</measure>
    <time_frame>During the 60th postoperative days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Common Terminology Criteria for Adverse Events v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>During the 60th postoperative days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months (M3), 6 months (M6) and 12 months (M12) after surgery +/- HIPEC procedure.</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC questionnaires QLQ-C30 and QLQ-STO 22</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Curative Gastrectomy + HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curative Gastrectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Curative gastrectomy with D1-D2 lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin</intervention_name>
    <description>After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.</description>
    <arm_group_label>Curative Gastrectomy + HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Curative gastrectomy</intervention_name>
    <description>All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas</description>
    <arm_group_label>Curative Gastrectomy + HIPEC</arm_group_label>
    <arm_group_label>Curative Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 &lt; age ≤ 75 years old

          -  White blood cells &gt; 3,500/mm3, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3

          -  Good renal functions, serum creatinine values being &lt; 1.5 mg/dl and creatinine
             clearance &gt; 60 ml/min

          -  Performance Status ≤1, Karnofsky Index ≥ 70%

          -  Serum bilirubin ≤ 2 mg/dl

          -  Having given written informed consent prior to any procedure related to the study.

          -  Covered by a Health System where applicable, and/or in compliance with the
             recommendations of the national laws in force relating to biomedical research

          -  Not under any administrative or legal supervision

          -  Histologically evidenced resectable T3 or T4 gastric adenocarcinoma for which a
             curative gastrectomy is scheduled, with invasion into the serosa AND/OR lymph node
             metastasis (determined from data obtained by endoscopic ultrasound and chest, abdomen
             and pelvis CT scan) AND/OR positive peritoneal cytology (sampled during the
             preoperative laparoscopy).

        AND/OR

          -  Perforated gastric adenocarcinoma AND/OR

          -  Siewert III adenocarcinoma of the cardia for which a gastrectomy by exclusive
             abdominal laparotomy is scheduled

          -  Females of childbearing age potential and male subjects with partners of childbearing
             potential using efficient contraceptive measures (as judged by the
             investigator).Subjects randomised in the arm with HIPEC should be informed and accept
             that these requirements should also extend to :

               -  4 months after the treatment with Oxaliplatin for female subjects,

               -  6 months after the treatment with Oxaliplatin for male subjects.

        Exclusion Criteria:

          -  Prior malignant tumors with detectable signs of recurrence

          -  Gastric stump adenocarcinoma

          -  Presence of comorbidities, notably serious chronic diseases or organ failure General
             conditions

          -  Any subject in exclusion period of a previous study according to applicable
             regulations

          -  Pregnancy or breastfeeding

          -  Females of childbearing age potential or male subjects with partners of childbearing
             potential not using medically accepted contraceptive measures, as judged by the
             investigator Interfering substance

          -  Contraindication to any drug contained in the chemotherapy regimen Specific to the
             study

          -  Life threatening toxicity before surgery

          -  Distant metastases (liver, lung. ovaries, etc)

          -  Tumoral infiltration of the head or body of the pancreas

          -  Patients presenting an adenocarcinoma of the cardia Siewert I or II

          -  Existence of macroscopic peritoneal implants

          -  Patients with clinically significant ascites (&gt; 500 cc) even if cytology is negative
             for cancer cells, in the absence of other non-malignant causes of ascites
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier GLEHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Chirurgie Générale Digestive et Endocrinienne, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier GLEHEN, MD</last_name>
    <phone>4 78 86 13 77</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.glehen@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurent VILLENEUVE</last_name>
    <phone>4 78 86 45 36</phone>
    <phone_ext>+33</phone_ext>
    <email>laurent.villeneuve@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive Oncologique, CLCC Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gérard LORIMIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Jean Minjoz, CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno HEYD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Viscérale, CLCC François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marc GUILLOIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Viscérale, CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis PEZET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale et Digestive, Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simon MSIKA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick RAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive et de l'Urgence, Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine ARVIEUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CLCC Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre MEEUS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François QUENET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CLCC René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques PAINEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Archet II</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marc BEREDER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc POCARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale Digestive et Endocrinienne, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GLEHEN, MD</last_name>
      <phone>4 78 86 13 77</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.glehen@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle BONNEFOY</last_name>
      <phone>4 78 86 59 84</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.bonnefoy01@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier GLEHEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive et de Physiologie Digestive, Hôpital Ch. Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Jacques TUECH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre MICHEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jack PORCHERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Viscérale et Digestive, Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cécile BRIGAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale et Digestive, Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas CARRERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive Oncologique, CLCC Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric MARCHAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Digestive et Hépatobiliaire, Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique ELIAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>June 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric adenocarcinoma</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Signet ring cell</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
